Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

BAYER (BAYN)
Mes dernières consult.
Most popular
Real-time Quote. Real-time Tradegate - 10/18 05:12:30 pm
118.706 EUR   +0.09%
03:01p BAYER : to fund three youth-led food security projects
10/17 BAYER : foundations bring tech pioneers physicians and social entrep..
10/14DJBAYER : Unloads Assets to Aid Deal -- WSJ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Bayer : Halts Phase 3 Study on New Xarelto Indication

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/06/2017 | 08:44am CEST
   By Sarah Sloat 
 

Bayer AG (>> Bayer) said late Thursday it halted a phase 3 study for the use of blood-thinning drug Xarelto because it didn't show improved efficacy compared with another treatment using aspirin.

The Navigate Esus study was testing Xarelto for the secondary prevention of strokes and systemic embolism in patients who recently had an embolic stroke of undetermined source.

Researchers stopped the trial early because the Xarelto and aspirin arms of the study showed comparable efficacy, and there was little chance of an overall benefit if it were completed, the German pharmaceutical and chemicals company said.

"While bleeding rates were low overall, an increase in bleeding was observed in the [Xarelto] arm compared to the low-dose aspirin arm," Bayer said.

Xarelto, also known as rivaroxaban, is a prescription anticoagulant which been approved for seven indications. The drug contributed just over 2.9 billion euros ($3.4 billion) in sales to Bayer's pharmaceutical division last year.

The drug was developed jointly by Bayer and Janssen Pharmaceuticals, a unit of Johnson & Johnson (>> Johnson & Johnson). It is marketed outside the U.S. by Bayer and within the U.S. by Janssen.

Write to Sarah Sloat at [email protected]

Stocks mentioned in the article : Bayer, Johnson & Johnson
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER
03:01p BAYER : to fund three youth-led food security projects
10/17 BAYER : foundations bring tech pioneers physicians and social entrepreneurs to t..
10/16 BAYER : Health and Human Services Department (HHS); Food and Drug Administration..
10/14DJBAYER : Unloads Assets to Aid Deal -- WSJ
10/13 BASF CEO says to look at more seed M&A after Bayer deal
10/13 Bayer sells units to be able to complete Monsanto takeover
10/13 BAYER : foundations bring tech pioneers, physicians and social entrepreneurs to ..
10/13DJBASF to Buy Large Parts of Bayer's Seed and Non-Selective Herbicide Businesse..
10/13 BAYER AKTIENGESELLSCHAFT : Release according to Article 26, Section 1 of the WpH..
10/13DJBASF : Signs Agreement To Acquire Significant Parts Of Bayer's Seed And Non-Sele..
More news
News from SeekingAlpha
10/17 Monsanto Ending On A Position Of Strength
10/16 BASF (BASFY) To Acquire Significant Parts Of Bayer's (BAYZF) Seed And Non-Sel..
10/14 BASF Buys Bayer's Crop Science Assets At A Fair Price
10/13 WALL STREET BREAKFAST : The Beat Goes On For Global Stocks As Records Continue T..
10/13 Bayer to sell seed, herbicide assets to BASF for $7B, subject to Monsanto dea..
Financials (€)
Sales 2017 48 365 M
EBIT 2017 9 231 M
Net income 2017 5 397 M
Debt 2017 12 235 M
Yield 2017 2,34%
P/E ratio 2017 19,50
P/E ratio 2018 17,64
EV / Sales 2017 2,28x
EV / Sales 2018 2,18x
Capitalization 98 076 M
Chart BAYER
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Technical analysis trends BAYER
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 121 €
Spread / Average Target 2,0%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER19.19%115 363
JOHNSON & JOHNSON18.42%377 880
NOVARTIS13.23%225 650
ROCHE HOLDING LTD.5.20%217 022
PFIZER11.88%215 576
MERCK AND COMPANY7.68%172 423